<DOC>
	<DOCNO>NCT02547831</DOCNO>
	<brief_summary>This prospective , multicenter observational study umbrella ISG ( Italian Sarcoma Group ) evaluate local progression-free survival 3 year patient affect extra-abdominal primary fibromatosis manage front-line conservative approach treat case demonstrate progressive disease . All patient include placed wait see approach shift treatment case document radiological progressive disease . For patient primarily evaluate suspect desmoid tumor , core-needle biopsy ( eventually CT/ultrasound guide ) obtain histological diagnosis mutational analysis CTNNB1 exon 3 ( gene encode Beta-catenin ) . If incisional biopsy surgical procedure do elsewhere , sample request histological confirmation mutational analysis ( centralization investigator Institution ) . In case progression 3 month , define tumor growth document radiologically ( contrast enhance MRI ) Response Evaluation Criteria Solid Tumors ( RECIST ) , administer treatment propose registered clinical database.The choice treatment eventually possibility continuation `` surveillance '' discretion Institution 's Multidisciplinary Sarcoma Committee part clinical trial consent patient .</brief_summary>
	<brief_title>Tailored Beta-catenin Mutational Approach Extra-abdominal Sporadic Desmoids Tumor Patients</brief_title>
	<detailed_description>This prospective , multicenter observational study umbrella ISG ( Italian Sarcoma Group ) evaluate local progression-free survival 3 year patient affect extra-abdominal primary fibromatosis manage front-line conservative approach treat case demonstrate progressive disease . All patient include placed wait see approach shift treatment case document radiological progressive disease . For patient primarily evaluate suspect desmoid tumor , core-needle biopsy ( eventually CT/ultrasound guide ) obtain histological diagnosis mutational analysis CTNNB1 exon 3 ( gene encode Beta-catenin ) . If incisional biopsy surgical procedure do elsewhere , sample request histological confirmation mutational analysis ( centralization Institution ) select case new biopsy obtain . In case progression 3 month , define tumor growth document radiologically ( contrast enhance MRI ) Response Evaluation Criteria Solid Tumors ( RECIST ) , administer treatment propose registered clinical database ( radiological evaluation centralize Istituto Rizzoli , Bologna- Dr. Vandel ) . Therapy include follow option : - Surgery - Radiotherapy - Medical treatment include hormonal therapy ( e.g. , tamoxifen , toremifene ) , low-dose chemotherapy ( e.g. , methotrexate vinorelbine/vinblastine ) , NSAIDs ( e.g. , celecoxib ) , target therapy ( Glivec ) - Combination The choice treatment eventually possibility continuation `` surveillance '' discretion Institution 's Multidisciplinary Sarcoma Committee part clinical trial consent patient .</detailed_description>
	<mesh_term>Fibromatosis , Aggressive</mesh_term>
	<mesh_term>Fibroma</mesh_term>
	<criteria>Sporadic form No age limit ( pediatric patient include ) Extra abdominal fibromatosis primary previous inadequate resection ( R2 ) extremity , chest/abdominal wall head/neck Histological diagnosis accord WHO criteria do biopsy surgical specimen pathologist Diagnostic radiological exam perform ( contrast enhance MRI T1 T2 weight ) Signed informed consent form Adequate compliance patient plan followup Controindication MRI Familialtype desmoid Recurrence Extraabdominal primary fibromatosis resect R0/R1 margin Patients treatment desmoid tumor Other malignancy within past 5 year , exception carcinoma situ cervix basocellular skin cancer treat eradicate intent Serious psychiatric disease precludes inform consent limit compliance Medical disease request treatment correspond one drug currently use desmoid tumor [ hormonal therapy ( e.g. , tamoxifen/toremifene , lowdose chemotherapy ( e.g. , methotrexate vinorelbine/vinblastine ) , NSAIDs ( e.g. , celecoxib ) , target therapy ( Glivec ) ] Impossibility ensure adequate followup</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>